PCM
IMUX icon

Penserra Capital Management’s Immunic IMUX Stock Holding History

Penserra Capital Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-60
Closed -$5K – 1443
2021
Q3 		$5K Buy
60
+10
+20% +$984 ﹤0.01% 1406
2021
Q2 		$6K Buy
50
+1
+2% +$138 ﹤0.01% 1309
2021
Q1 		$7K Buy
49
+1
+2% +$170 ﹤0.01% 1062
2020
Q4 		$7K Buy
+48
New +$8.62K ﹤0.01% 959

Other funds holding IMUX

OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Penserra Capital Management's IMUX Position: Q4 2021 in Review

Penserra Capital Management sold out of Immunic (IMUX) in Q4 2021, closing a stake of 60 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in IMUX in Q4 2020 and held it in 4 quarters. The position peaked at $7K in Q1 2021. 67 funds tracked by Wall St. Rank hold IMUX as of Q4 2021.

  • Penserra Capital Management reported no remaining Immunic position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 60 Immunic shares in Q4 2021, an estimated $5K.
  • Penserra Capital Management first reported a position in Immunic in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Immunic position peaked at $7K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Immunic as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.